• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up.

作者信息

Dreyling Martin, Goy Andre, Hess Georg, Kahl Brad S, Hernández-Rivas José-Ángel, Schuier Natasha, Qi Keqin, Deshpande Sanjay, Zhu Angeline, Parisi Lori, Wang Michael L

机构信息

Department of Medicine III, University Hospital, Ludwig Maximilians University, Munich, Germany.

Department of Hematology & Oncology, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, USA.

出版信息

Hemasphere. 2022 Apr 13;6(5):e712. doi: 10.1097/HS9.0000000000000712. eCollection 2022 May.

DOI:10.1097/HS9.0000000000000712
PMID:35441128
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9010121/
Abstract
摘要

相似文献

1
Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up.依鲁替尼治疗复发/难治性套细胞淋巴瘤患者的长期结局：三项临床试验近10年随访的汇总分析
Hemasphere. 2022 Apr 13;6(5):e712. doi: 10.1097/HS9.0000000000000712. eCollection 2022 May.
2
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.依鲁替尼对比替西罗莫司治疗复发或难治性套细胞淋巴瘤患者：一项国际性、随机、开放标签、3 期研究。
Lancet. 2016 Feb 20;387(10020):770-8. doi: 10.1016/S0140-6736(15)00667-4. Epub 2015 Dec 7.
3
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.Umbralisib联合伊布替尼治疗复发或难治性慢性淋巴细胞白血病或套细胞淋巴瘤患者：一项多中心1-1b期研究
Lancet Haematol. 2019 Jan;6(1):e38-e47. doi: 10.1016/S2352-3026(18)30196-0. Epub 2018 Dec 14.
4
Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience.真实世界经验中伊布替尼治疗复发或难治性套细胞淋巴瘤的临床结局。
Cancer Med. 2019 Nov;8(16):6860-6870. doi: 10.1002/cam4.2565. Epub 2019 Sep 27.
5
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).来那度胺治疗伊布替尼治疗后复发/进展或不耐受/难治的套细胞淋巴瘤患者的观察性研究（MCL-004）。
J Hematol Oncol. 2017 Nov 2;10(1):171. doi: 10.1186/s13045-017-0537-5.
6
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.伊布替尼、来那度胺和利妥昔单抗治疗复发或难治性套细胞淋巴瘤（PHILEMON）：一项多中心、开放标签、单臂、2期试验。
Lancet Haematol. 2018 Mar;5(3):e109-e116. doi: 10.1016/S2352-3026(18)30018-8. Epub 2018 Jan 29.
7
Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.复发/难治性套细胞淋巴瘤中依鲁替尼治疗的预测因素及结果——一项“真实世界”研究
Hematol Oncol. 2017 Dec;35(4):528-535. doi: 10.1002/hon.2380. Epub 2017 Jan 8.
8
A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.新型布鲁顿酪氨酸激酶抑制剂依鲁替尼的综述
J Oncol Pharm Pract. 2016 Feb;22(1):92-104. doi: 10.1177/1078155214561281. Epub 2014 Nov 25.
9
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.伊布替尼治疗复发或难治性套细胞淋巴瘤中的 BTK。
N Engl J Med. 2013 Aug 8;369(6):507-16. doi: 10.1056/NEJMoa1306220. Epub 2013 Jun 19.
10
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.依鲁替尼联合利妥昔单抗治疗复发或难治性套细胞淋巴瘤：单中心、开放标签、2 期临床试验。
Lancet Oncol. 2016 Jan;17(1):48-56. doi: 10.1016/S1470-2045(15)00438-6. Epub 2015 Nov 28.

引用本文的文献

1
Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: a Danish population-based study.伊布替尼治疗复发或难治性套细胞淋巴瘤的真实世界疗效：一项基于丹麦人群的研究。
Blood Neoplasia. 2025 Jun 9;2(3):100128. doi: 10.1016/j.bneo.2025.100128. eCollection 2025 Aug.
2
Molecular pathology of lymphoma and its treatment strategies: from mechanistic elucidation to precision medicine.淋巴瘤的分子病理学及其治疗策略：从机制阐明到精准医学
Front Immunol. 2025 Jul 9;16:1620895. doi: 10.3389/fimmu.2025.1620895. eCollection 2025.
3
First Line Therapy in Mantle Cell Lymphoma-The Role of BTKi in the Initial Treatment of Transplant-Eligible and -Ineligible Patients.

本文引用的文献

1
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study.初治复发/难治性年轻套细胞淋巴瘤患者的结局：MANTLE-FIRST 研究结果。
Leukemia. 2021 Mar;35(3):787-795. doi: 10.1038/s41375-020-01013-3. Epub 2020 Aug 11.
2
Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse.现代时代复发性套细胞淋巴瘤患者的生存模式：每次复发后反应持续时间和生存时间逐渐缩短。
Blood Cancer J. 2019 May 20;9(6):50. doi: 10.1038/s41408-019-0209-5.
3
Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis.
套细胞淋巴瘤的一线治疗——BTKi在适合和不适合移植患者初始治疗中的作用
Hematol Oncol. 2025 Jun;43 Suppl 2(Suppl 2):e70073. doi: 10.1002/hon.70073.
4
Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy.序贯使用布鲁顿酪氨酸激酶抑制剂（BTKi）和维奈克拉治疗套细胞淋巴瘤的耐药机制与克隆动力学
J Pathol. 2025 Aug;266(4-5):395-404. doi: 10.1002/path.6434. Epub 2025 May 15.
5
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.阿卡替尼联合苯达莫司汀-利妥昔单抗治疗初治套细胞淋巴瘤
J Clin Oncol. 2025 Jul 10;43(20):2276-2284. doi: 10.1200/JCO-25-00690. Epub 2025 May 1.
6
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL.巩固治疗与否：自体干细胞移植在套细胞淋巴瘤中的作用
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):42-47. doi: 10.1182/hematology.2024000546.
7
Your chemo is no good here: management of high-risk MCL.在这里，你的化疗方案效果不佳：高危套细胞淋巴瘤的管理
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):34-41. doi: 10.1182/hematology.2024000658.
8
Monitoring of molecular responses to tirabrutinib in a cohort of exceptional responders with relapsed/refractory mantle cell lymphoma.对一组复发/难治性套细胞淋巴瘤的特殊反应者队列中替拉布替尼分子反应的监测。
EJHaem. 2024 Jun 24;5(4):896-899. doi: 10.1002/jha2.966. eCollection 2024 Aug.
9
Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis.在英国，用于复发或难治性套细胞淋巴瘤的brexucabtagene autoleucel：一项真实世界的意向性治疗分析。
Hemasphere. 2024 Jun 13;8(6):e87. doi: 10.1002/hem3.87. eCollection 2024 Jun.
10
Real-World Evidence of Relapsed/Refractory Mantle Cell Lymphoma Patients and Treatments: A Systematic Review.复发/难治性套细胞淋巴瘤患者及治疗的真实世界证据：一项系统评价
J Blood Med. 2024 May 25;15:239-254. doi: 10.2147/JBM.S463946. eCollection 2024.
依鲁替尼治疗复发/难治性套细胞淋巴瘤：汇总分析的3.5年延长随访结果
Haematologica. 2019 May;104(5):e211-e214. doi: 10.3324/haematol.2018.205229. Epub 2018 Nov 15.
4
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death.基于大剂量阿糖胞苷方案的套细胞淋巴瘤进展时间可确定患者的死亡风险。
Br J Haematol. 2019 Jun;185(5):940-944. doi: 10.1111/bjh.15643. Epub 2018 Nov 8.
5
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.新诊断及复发的套细胞淋巴瘤：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2017 Jul 1;28(suppl_4):iv62-iv71. doi: 10.1093/annonc/mdx223.
6
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.370例接受依鲁替尼治疗的套细胞淋巴瘤患者的结局：三项开放标签研究的汇总分析
Br J Haematol. 2017 Nov;179(3):430-438. doi: 10.1111/bjh.14870. Epub 2017 Aug 18.
7
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.依鲁替尼对比替西罗莫司治疗复发或难治性套细胞淋巴瘤患者：一项国际性、随机、开放标签、3 期研究。
Lancet. 2016 Feb 20;387(10020):770-8. doi: 10.1016/S0140-6736(15)00667-4. Epub 2015 Dec 7.
8
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.伊布替尼治疗复发或难治性套细胞淋巴瘤中的 BTK。
N Engl J Med. 2013 Aug 8;369(6):507-16. doi: 10.1056/NEJMoa1306220. Epub 2013 Jun 19.